Core Insights - Novo Nordisk's recent trial data for its obesity drug CagriSema has underperformed compared to Eli Lilly's Zepbound, raising concerns about Novo's competitiveness in the weight-loss drug market [1] - Following the trial results, Novo's shares dropped by 16%, while Lilly's shares increased by 5%, indicating a shift in market sentiment towards Lilly's products [1] - Analysts express skepticism about Novo's ability to regain market share, citing repeated disappointments with CagriSema and the strong positioning of Lilly's portfolio [1] Novo Nordisk's Performance - CagriSema achieved a 23% reduction in body weight over 84 weeks, compared to a 25.5% reduction for Lilly's tirzepatide [1] - The trial results align with previous data for CagriSema but are seen as inferior to Lilly's offerings, which could solidify Lilly's dominance in the obesity market [1] - Novo's management attempted to downplay the trial results, but analysts and investors remain unconvinced, questioning the drug's value proposition [1] Market Dynamics - The obesity drug market is increasingly favoring Lilly, which has a stronger product range and is expected to receive U.S. approval for its weight-loss pill in April [1] - Novo's historical lead in the obesity drug market, particularly with the launch of Wegovy in 2021, has diminished as Lilly's valuation has surged to a trillion dollars [1] - Analysts suggest that Novo may struggle to compete effectively against Lilly's Zepbound, which is already well-established in the market [1]

Core Insights - Pfizer has entered a licensing agreement with Sciwind Biosciences for the type 2 diabetes treatment ecnoglutide, with potential payments reaching up to $495 million based on milestone achievements [1] - This deal is a strategic move for Pfizer to enhance its presence in the metabolic field within China [1] - Ecnoglutide is part of the GLP-1 receptor agonists class, which has attracted investments from various pharmaceutical companies [1] Company Developments - Sciwind Biosciences has received approval for ecnoglutide in China as of January and is also pursuing approval for an experimental version aimed at weight management [1] - The agreement includes an upfront fee and additional payments linked to regulatory and sales milestones, specifically for the commercialization of ecnoglutide in mainland China [1] - Unlike competitors' products, ecnoglutide will not be included in China's state-run health insurance for type 2 diabetes treatments [1]

【国泰海通医药】春节期间创新药领域重点新闻梳理-海外公司 1）2/12 公司自2019年起任职的CEO PaulHudson不再续聘，前默沙东CEO BelénGarijo上任（#过去3年赛诺菲临床失 败多管线青黄不接）； 2）2/17 赛诺菲&TEVA更新了共同开发的TL1A单抗duvakitug IIb期更长期随访的数据，其中44周时接受900mg药物维 持治疗的UC患者临床缓解率达到58%（较安 【国泰海通医药】春节期间创新药领域重点新闻梳理-海外公司 赛诺菲： 1）2/12 公司自2019年起任职的CEO PaulHudson不再续聘，前默沙东CEO BelénGarijo上任（#过去3年赛诺菲临床失 败多管线青黄不接）； 2）2/17 赛诺菲&TEVA更新了共同开发的TL1A单抗duvakitug IIb期更长期随访的数据，其中44周时接受900mg药物维 持治疗的UC患者临床缓解率达到58%（较安慰剂提高27%），CD患者的内镜应答率达到55%（较安慰剂提高 35%），相比16周均有提高，数据亮眼； 阿斯利康： 1）2/20 FDA批准阿斯利康阿克替尼联合维奈托克全口服、固定疗程方案针对一线CLL ...

Investment Rating - The report suggests a positive outlook for Indonesia's trade integration efforts, indicating potential GDP gains through structural reforms and trade liberalization, aiming for high-income status by 2045 [5][12]. Core Insights - Indonesia is pursuing greater trade openness to leverage external demand for economic growth, with a focus on reducing non-tariff barriers and implementing structural reforms to enhance trade integration [5][12]. - The analysis indicates that significant GDP gains can be achieved through unilateral actions to reduce non-tariff barriers, complemented by trade agreements with major partners [5][12]. - Structural reforms in human capital and logistics are essential to further enhance trade integration and reduce trade costs, thereby broadening Indonesia's comparative advantages across sectors [5][12]. Summary by Sections A. Key Policies and Structural Factors Affecting Trade - Indonesia's average tariffs on manufactured goods have declined, but non-tariff barriers remain elevated compared to regional peers, indicating room for further reductions [18][19]. - The impact of non-tariff barriers on trade is substantial, with potential GDP increases of 5% from removing major NTBs [19]. B. Model and Scenario Description - A quantitative trade model is used to assess the implications of deeper trade integration, focusing on reducing non-tariff barriers and enhancing logistics and human capital [33][36]. C. Main Results - The ambitious trade integration scenario could boost Indonesia's real GDP by 4.1% in the medium to long term, primarily through lower non-tariff barriers and improved access to intermediate goods [41][42]. - Unilateral reductions in non-tariff barriers can benefit many sectors, leading to overall GDP increases despite some sectoral reallocations [43][46]. D. Exploiting Complementarities between Trade Integration and Other Structural Reforms - Structural reforms are crucial for achieving high-income status, with key areas including logistics, governance, and human capital development [53][54]. - Trade liberalization can support the development of new comparative advantages, particularly in GVC-linked sectors and modern services [53][54].

【国泰海通医药】春节期间创新药领域重点新闻梳理-上市公司 恒瑞医药： 1）2/12 CDE官网显示公司递交了ANGPTL3单抗SHR-1918针对HOFH的上市申请。 目前公司暂未披露1918的III期临床结果； 1）2/20 公司公告阿美替尼已获欧洲药品管理局EMA批准在欧盟上市，用于EGFR19del或L858RNSCLC一线治疗， 以及T790MNSCLC治疗； 石药集团： 1）2/16 公司公告旗下受体偏向性GLP1/GIP激动剂月制剂SYH2082在美国获批临床； 信立泰： 翰森制药： 1）2/20 公司公告阿美替尼已获欧洲药品管理局EMA批准在欧盟上市，用于EGFR19del或L858RNSCLC一线治疗， 以及T790MNSCLC治 【国泰海通医药】春节期间创新药领域重点新闻梳理-上市公司 恒瑞医药： 1）2/12 CDE官网显示公司递交了ANGPTL3单抗SHR-1918针对HOFH的上市申请。 目前公司暂未披露1918的III期临床结果； 翰森制药： 1）2/20 公司在《欧洲呼吸杂志子刊-开放研究》ERJ OPEN RESEARCH上披露了IL17RB单抗SM17针对CRSWNP和 IPF ...

Summary of Key Points from Conference Call Industry Overview - The conference call discusses the global business development (BD) activities in the pharmaceutical sector during the Chinese New Year period from February 13 to February 23, 2026, highlighting a total of 18 BD transactions globally [1] Core Insights and Arguments - **Key Transactions**: - Qinhai Bio licensed its MAT2A inhibitor (GH31), which has received IND approval in China and the US and is currently in Phase I clinical trials, to Gilead. Qinhai will receive an upfront payment of $80 million, $1.45 billion in milestone payments, and a tiered double-digit percentage royalty based on net sales [1] - Other notable transactions include: - Novartis partnered with Unnatural Products to develop macrocyclic peptide drugs, focusing on cardiovascular applications, with Unnatural Products receiving an upfront payment of $100 million and potential milestone payments of $1.7 billion [1] - Eli Lilly acquired global rights for the IL6 monoclonal antibody clazakizumab from CSL for all indications except end-stage renal disease, with CSL receiving an upfront payment of $100 million [1] - Merck collaborated with Mayo Clinic to integrate clinical and genomic data, focusing on early research translation in inflammatory bowel disease, skin diseases, and neurology [1] - **Year-to-Date Transactions**: - From January 1 to February 23, 2026, there have been 36 BD transactions involving Chinese companies, with 13 of these transactions involving multinational corporations (MNCs) [1] Additional Important Insights - **Comparison with Previous Year**: - In comparison, there were 26 BD transactions during the same period in 2025, with only 3 involving MNCs [2] - **Future Outlook**: - The analysis indicates that MNCs have increased their focus on Chinese BD teams and asset searches since the second half of 2025, suggesting a positive outlook for more BD transactions involving Chinese assets and MNCs in 2026 [2]

南方财经2月24日电，国发股份(600538.SH)2026年2月24日公告，回复了上海证券交易所关于其2025年 度业绩预告事项的问询函。交易所主要关注三大问题：业绩构成与合规性、医药流通业务增长合理性， 以及大额商誉减值。关于业绩，问询函要求公司说明营业收入扣除情况。公司回复称，2025年预计营收 约3.3亿元，扣除与主营业务无关的收入248.08万元后，营收为3.27亿元。分业务看，医药流通业务收入 占比近58%，同比增长4.43%；而司法IVD与医药制造业务收入分别下降10%和23.44%。公司前五大客 户在医药流通板块稳定，在司法IVD板块因招投标竞争加剧变动较大，并称不存在收入确认政策变更或 通过新客户实现异常交易的情形。对于医药流通业务收入增长，交易所问询其是否与行业趋势匹配。公 司解释，增长主要源于医院销售，特别是集采品种和麻精药品的销售增加。业务交货以送货上门或快递 为主，以客户签收作为收入确认时点。公司认为其4.43%的增长率，与北部湾区域医药市场约4%-4.5% 的增速及同行业公司表现相符。针对连续大额商誉减值，交易所要求说明减值是否充分。公司披露，其 收购的子公司高盛生物因公安客户预算 ...

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of common stock of Corcept Therapeutics Incorporated during the specified Class Period, indicating potential legal issues surrounding the company's stock performance and disclosures [1]. Group 1: Class Action Details - The class action lawsuit is on behalf of investors who purchased Corcept common stock between October 31, 2024, and December 30, 2025 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must be appointed by April 21, 2026, to represent other class members in the litigation [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company [4]. - The firm has been ranked No. 1 for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. Group 3: Case Specifics - The lawsuit claims that Corcept misrepresented the strength of clinical trials for relacorilant, suggesting it was a strong candidate for FDA approval, while the FDA had raised concerns about the clinical evidence [5]. - The defendants allegedly assured investors that there were no impediments to the New Drug Application (NDA) approval, which was later contradicted by the FDA's concerns [5]. - When the true situation regarding the NDA was revealed, investors reportedly suffered damages [5].

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Corcept (CORT) To Contact Him Directly To Discuss Their Options If you purchased or acquired Corcept common stock between October 31, 2024, and December 30, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Melissa Fortunato directly at (212) 355-4648. Click here to participate in the action. NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- What’s Happeni ...

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP announces that a class action lawsuit has been filed on behalf of investors who acquired Corcept Therapeutics Incorporated ("Corcept†or the "Company†) (NASDAQ:CORT) securities during the period of October 31, 2024 through December 30, 2025, inclusive ("the Class Period†). If you suffered a loss on your Corcept investments, you have until April 21, 2026 to request lead plaintiff appointment. Courts do not consider lead plaintiff app. ...